Summary

The biomarkers market is expected to reach USD 93.8 billion in 2029 from USD 57.7 billion in 2024, at a CAGR of 10.2% during the forecast period.
The growth of this market can be attributed to the advantage that these assay kits offer standardized and optimized protocols, facilitating accurate and efficient analysis of biomarkers in various biological samples, thus contributing significantly to diagnostic and research endeavors in healthcare. Further, advances in technologies such as genomics, proteomics, metabolomics, and next-generation sequencing have expanded the capabilities of biomarkers. This has led to the development of novel biomarkers with enhanced sensitivity, specificity, and predictive value.
“The predictive biomarkers segment accounted for the largest share by efficacy biomarkers in 2023.”
The biomarkers market by type is segmented into safety biomarkers, efficacy biomarkers, and validation biomarkers. In 2023, the predictive biomarkers segment accounted for the largest share of the efficacy biomarkers segment in the global biomarkers market. Factors such as these biomarkers help tailor treatment strategies to individual patients, maximizing the likelihood of a favorable response while minimizing potential adverse effects. Examples include genetic mutations that predict response to targeted therapies are driving the growth of this market.
“The Asia Pacific region is growing at the highest CAGR in the biomarkers market during the forecast period of 2024-2029.”
The Asia Pacific region is expected to grow at the highest growth rate during the forecast period. Various factors including the large patient pool undergoing advanced medical testing and policy programs to provide effective care to cancer patients are factors driving the high growth of the APAC market.
Increased research activities from pharmaceutical and biotechnology companies to develop novel drug therapies are expected to boost the growth of the biomarkers market in the Asia Pacific region. As the region continues to invest in drug development, there is a growing demand for biomarkers supporting drug discovery efforts.
The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: C-level Executives - 55%, Director-level - 20%, and Others - 25%
• By Region: North America -45%, Europe -20%, Asia-Pacific -20%, Latin America -10%, Middle East -3%, and Africa-2%.
List of Companies Profiled in the Report:
• F. Hoffmann-La Roche Ltd (Switzerland)
• Merck KGaA (Germany)
• Thermo Fisher Scientific Inc. (US)
• Abbott (US)
• QIAGEN (Netherlands)
• Revvity (US)
• Laboratory Corporation of America Holdings (US)
• Charles River Laboratories (US)
• Bio-Rad Laboratories, Inc. (US)
• Eurofins Scientific (Luxembourg)
• BIOMÉRIEUX (France)
• Agilent Technologies, Inc. (US)
• JSR Corporation (Japan)
• Quanterix (US)
• MESO SCALE DIAGNOSTICS, LLC. (US)
• EKF Diagnostics (UK)
• Celerion (US)
• Standard BioTools (US)
• Sebia (France)
• BioAgilytix Labs (US)
• StressMarq Biosciences Inc. (Canada)
• NorthEast BioAnalytical Laboratories LLC (US)
• Signosis, Inc. (US)
• Serimmune (US)
• TheraIndx Lifesciences Pvt. Ltd. (India)
• Synexa Life Sciences BV (Netherlands)
• Diatech Pharmacogenetics (Italy)
• Singulex, Inc. (US)
• R-Biopharm AG (Germany)
• Proteome Sciences (UK)

Research Coverage:

This research report categorizes the biomarkers market by product & service (consumables (assay kits, columns & filters, reagents & chemicals), services, and software), type (safety biomarkers, efficacy biomarkers (surrogate biomarkers, pharmacodynamics biomarkers, predictive biomarkers, and prognostic biomarkers), and validation biomarkers), research area (genomics, proteomics, metabolomics, and other research area), technology (immunoassays (western blot, ELISA, and protein microarray), NGS, PCR, mass spectrometry, chromatography, and other technologies), disease indication (cancer, infectious diseases, cardiovascular disorders, immunological disorders, neurological disorders, and other disease indications), application (clinical diagnostics, drug discovery & development, personalized medicines, clinical research, and other applications), end user (pharmaceutical & biotechnologies companies, hospitals & diagnostics laboratories, research & academic institutes, and other end users), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The report provides in-depth information on significant factors influencing the growth of the biomarkers market, including drivers, trends, challenges, and opportunities. A thorough analysis of major industry players has been undertaken to provide insights into their business profiles, products/services, key strategies, collaborations, partnerships, and agreements. Additionally, the report encompasses recent developments such as new product launches, and acquisitions within the biomarkers market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall biomarkers market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
• Analysis of key drivers (Growing significance of biomarkers in drug discovery and development, Growing importance of companion diagnostics, Increase in global prevalence of cancer, Growing importance of biomarkers for rare conditions, Increase in funds and grants for biomarker research, Advancement in omics technologies and continuous product innovations), restraints (High capital investments and lengthy timelines for biomarker development, Disease complexity, and heterogeneity), opportunities (Shift towards personalized medicine and precision oncology, Enhanced collaboration among healthcare providers and key industry players, Emerging economies), and challenges (Challenges associated with quantification and validation of biomarkers, Challenges associated integration of complex data sets, Technical issues related to sample collection and storage) influencing the growth of the market.
• Product Development/Innovation: Detailed insights on newly launched products/services of the biomarkers market
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products/services, untapped geographies, recent developments, and investments in the biomarkers market
• Competitive Assessment: F. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Abbott (US), QIAGEN (Netherlands), Revvity (US), Laboratory Corporation of America Holdings (US), Charles River Laboratories (US), Bio-Rad Laboratories, Inc. (US), Eurofins Scientific (Luxembourg), BIOMÉRIEUX (France), Agilent Technologies, Inc. (US), JSR Corporation (Japan), Quanterix (US), MESO SCALE DIAGNOSTICS, LLC. (US), EKF Diagnostics (UK), Celerion (US), Standard BioTools (US), Sebia (France), BioAgilytix Labs (US), StressMarq Biosciences Inc. (Canada), NorthEast BioAnalytical Laboratories LLC (US), Signosis, Inc. (US), Serimmune (US), TheraIndx Lifesciences Pvt. Ltd. (India), Synexa Life Sciences BV (Netherlands), Diatech Pharmacogenetics (Italy), Singulex, Inc. (US), R-Biopharm AG (Germany), and Proteome Sciences (UK) among others in the market.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 67
1.1 STUDY OBJECTIVES 67
1.2 MARKET DEFINITION 67
1.2.1 INCLUSIONS AND EXCLUSIONS 68
1.3 MARKET SCOPE 69
1.3.1 MARKETS COVERED 69
1.3.2 REGIONS COVERED 70
1.3.3 YEARS CONSIDERED 70
1.4 CURRENCY CONSIDERED 71
1.5 STAKEHOLDERS 71
1.6 SUMMARY OF CHANGES 71
1.6.1 RECESSION IMPACT 72
2 RESEARCH METHODOLOGY 73
2.1 RESEARCH DATA 73
FIGURE 1 RESEARCH DESIGN 73
2.1.1 SECONDARY DATA 74
2.1.2 PRIMARY DATA 74
FIGURE 2 BREAKDOWN OF PRIMARIES: BIOMARKERS MARKET 75
2.2 MARKET ESTIMATION METHODOLOGY 76
FIGURE 3 BIOMARKERS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023 76
2.2.1 GLOBAL MARKET ESTIMATION 76
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023 77
FIGURE 5 ILLUSTRATIVE EXAMPLE OF HOFFMANN-LA ROCHE LTD.: REVENUE SHARE ANALYSIS (2023) 77
2.2.1.1 Insights of primary experts 79
FIGURE 6 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 79
2.2.2 SEGMENTAL MARKET SIZE ESTIMATION 79
FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 79
2.3 MARKET GROWTH RATE PROJECTIONS 80
FIGURE 8 BIOMARKERS MARKET (SUPPLY-SIDE): CAGR PROJECTIONS 81
TABLE 1 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 81
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 83
FIGURE 9 DATA TRIANGULATION METHODOLOGY 83
2.5 RESEARCH ASSUMPTIONS 84
2.6 LIMITATIONS 84
2.7 RISK ANALYSIS 85
2.8 RECESSION IMPACT ANALYSIS 85
3 EXECUTIVE SUMMARY 87
FIGURE 10 BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2024 VS. 2029 (USD MILLION) 87
FIGURE 11 BIOMARKERS MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION) 88
FIGURE 12 BIOMARKERS MARKET, BY RESEARCH AREA, 2024 VS. 2029 (USD MILLION) 88
FIGURE 13 BIOMARKERS MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION) 89
FIGURE 14 BIOMARKERS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION) 89
FIGURE 15 GEOGRAPHICAL SNAPSHOT OF BIOMARKERS MARKET 90
4 PREMIUM INSIGHTS 91
4.1 BIOMARKERS MARKET OVERVIEW 91
FIGURE 16 ADVANCEMENTS IN OMICS TECHNOLOGIES AND RISING DRUG DISCOVERY & DEVELOPMENT ACTIVITIES TO PROPEL MARKET 91
4.2 ASIA PACIFIC: BIOMARKERS MARKET, BY PRODUCT & SERVICE 92
FIGURE 17 CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2023 92
4.3 BIOMARKERS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 93
FIGURE 18 CHINA TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 93
4.4 BIOMARKERS MARKET SHARE, BY END USER (2023) 93
FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 93
5 MARKET OVERVIEW 94
5.1 INTRODUCTION 94
5.2 MARKET DYNAMICS 94
FIGURE 20 BIOMARKERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 94
TABLE 2 BIOMARKERS MARKET: IMPACT ANALYSIS 95
5.2.1 DRIVERS 96
5.2.1.1 Increasing use of biomarkers in drug discovery & development 96
5.2.1.2 Growing importance of companion diagnostics 96
5.2.1.3 Rising prevalence of cancer 97
TABLE 3 CANCER INCIDENCE, BY REGION (2040) 97
5.2.1.4 Increasing development of biomarkers for rare diseases 98
5.2.1.5 Increasing funds and grants for biomarker research 98
5.2.1.6 Advancements in omics technologies 99
TABLE 4 PRODUCT APPROVALS & LAUNCHES (2022–2024) 100
5.2.2 RESTRAINTS 101
5.2.2.1 High capital investment and extensive timelines for biomarker development 101
TABLE 5 TIME FRAME FOR BIOMARKER DEVELOPMENT 101
5.2.2.2 Disease complexity and heterogeneity 101
5.2.3 OPPORTUNITIES 102
5.2.3.1 Growing preference for personalized medicine and precision oncology 102
5.2.3.2 Technological innovations between healthcare providers and key industry players 102
5.2.3.3 High growth potential of emerging economies 103
5.2.4 CHALLENGES 103
5.2.4.1 Issues associated with quantification & validation of biomarkers 103
5.2.4.2 Complexities associated with data set integration 104
5.2.4.3 Technical issues related to sample collection and storage 104
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 105
FIGURE 21 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 106
5.4 REGULATORY LANDSCAPE 106
5.4.1 US 106
5.4.2 EUROPE 107
5.4.3 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 107
TABLE 6 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 107
TABLE 7 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 108
TABLE 8 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 110
TABLE 9 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 112
5.5 VALUE CHAIN ANALYSIS 113
FIGURE 22 BIOMARKERS MARKET: VALUE CHAIN ANALYSIS 114
5.6 TECHNOLOGICAL ANALYSIS 115
5.6.1 KEY TECHNOLOGIES 115
5.6.1.1 Immunoassays 115
5.6.1.1.1 Immunohistochemistry (IHC) 115
5.6.1.1.2 ELISA 115
5.6.1.2 Next-generation Sequencing (NGS) 116
5.6.1.3 Polymerase Chain Reaction (PCR) 116
5.6.1.4 In Situ Hybridization 116
5.6.1.5 Microarrays 117
5.6.1.6 Mass Spectrometry 117
5.6.2 COMPLIMENTARY TECHNOLOGIES 117
5.6.2.1 Liquid Biopsy 117
5.6.2.2 CRISPR 118
5.6.3 ADJACENT TECHNOLOGIES 118
5.6.3.1 Artificial Intelligence (AI) and Machine Learning (ML) 118
5.6.3.2 Sensors (Wearable Devices) 118
5.7 PRICING ANALYSIS 119
5.7.1 AVERAGE SELLING PRICE OF BIOMARKERS CONSUMABLES 119
TABLE 10 AVERAGE SELLING PRICE OF BIOMARKERS BY KEY PLAYERS 119
5.7.2 AVERAGE SELLING PRICE OF BIOMARKERS CONSUMABLES 119
TABLE 11 AVERAGE SELLING PRICE OF BIOMARKERS BY REGION 119
5.8 PATENT ANALYSIS 120
5.8.1 METHODOLOGY 120
5.8.2 PATENTS FILED, BY DOCUMENT TYPE, 2014–2024 120
TABLE 12 PATENTS FILED, 2014–2024 120
5.8.3 INNOVATION AND PATENT APPLICATIONS 120
FIGURE 23 NUMBER OF PATENTS GRANTED IN THE PAST 10 YEARS 120
5.8.4 TOP APPLICANTS 121
FIGURE 24 TOP TEN PLAYERS WITH HIGHEST NUMBER OF PATENT APPLICATIONS, 2014–2024 121
TABLE 13 TOP 20 PATENT OWNERS IN BIOMARKERS, 2014–2024 121
TABLE 14 INDICATIVE LIST OF PATENTS IN BIOMARKERS MARKET, 2022–2024 122
5.9 BIOMARKERS MARKET: SUPPLY CHAIN ANALYSIS 124
FIGURE 25 BIOMARKERS MARKET: SUPPLY CHAIN ANALYSIS 125
5.10 ECOSYSTEM ANALYSIS 125
FIGURE 26 BIOMARKERS MARKET: ECOSYSTEM ANALYSIS 125
5.10.1 BIOMARKER TESTING RAW MATERIAL SUPPLIERS 126
TABLE 15 BIOMARKERS MARKET: RAW MATERIAL SUPPLIERS 126
5.10.2 BIOMARKER TESTING PRODUCT VENDORS 126
TABLE 16 BIOMARKERS MARKET: PRODUCT VENDORS 126
5.10.3 BIOMARKER TESTING SERVICE PROVIDERS 127
TABLE 17 BIOMARKERS MARKET: SERVICE PROVIDERS 127
5.10.4 BIOMARKER TESTING END USERS 127
TABLE 18 BIOMARKERS MARKET: END USERS 127
5.10.5 BIOMARKER TESTING REGULATORY AUTHORITIES 128
TABLE 19 BIOMARKERS MARKET: REGULATORY AUTHORITIES 128
5.11 KEY CONFERENCES AND EVENTS, 2024–2025 128
TABLE 20 BIOMARKERS MARKET: LIST OF CONFERENCES AND EVENTS 128
5.12 KEY STAKEHOLDERS AND BUYING CRITERIA 130
5.12.1 KEY STAKEHOLDERS ON BUYING PROCESS 130
FIGURE 27 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF BIOMARKERS 130
5.12.2 BIOMARKERS MARKET: BUYING CRITERIA 131
FIGURE 28 KEY BUYING CRITERIA FOR END USERS 131
TABLE 21 BUYING CRITERIA FOR BIOMARKER PRODUCTS, BY END USER 131
5.13 PORTER’S FIVE FORCES ANALYSIS 132
TABLE 22 IMPACT OF PORTER’S FIVE FORCES ON BIOMARKERS MARKET 132
5.13.1 INTENSITY OF COMPETITIVE RIVALRY 133
5.13.2 BARGAINING POWER OF SUPPLIERS 133
5.13.3 BARGAINING POWER OF BUYERS 133
5.13.4 THREAT OF SUBSTITUTES 133
5.13.5 THREAT OF NEW ENTRANTS 133
5.14 INVESTMENT AND FUNDING SCENARIO 134
TABLE 23 US: CANCER BIOMARKER FUNDING, 2021–2024 134
6 BIOMARKERS MARKET, BY PRODUCT & SERVICE 135
6.1 INTRODUCTION 136
TABLE 24 BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 136
6.2 CONSUMABLES 136
TABLE 25 CONSUMABLES MARKET, BY REGION, 2022–2029 (USD MILLION) 137
TABLE 26 NORTH AMERICA: CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 137
TABLE 27 EUROPE: CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 138
TABLE 28 ASIA PACIFIC: CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 138
TABLE 29 LATIN AMERICA: CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 139
TABLE 30 MIDDLE EAST: CONSUMABLES MARKET, BY REGION, 2022–2029 (USD MILLION) 139
TABLE 31 GCC COUNTRIES: CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 139
TABLE 32 CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION) 140
6.2.1 ASSAY KITS 140
6.2.1.1 Usage in biomolecule detection, quantification, and characterization to boost demand 140
TABLE 33 ASSAY KITS MARKETS, BY REGION, 2022–2029 USD MILLION) 141
TABLE 34 NORTH AMERICA: ASSAY KITS MARKETS, BY COUNTRY, 2022–2029 (USD MILLION) 141
TABLE 35 EUROPE: ASSAY KITS MARKETS, BY COUNTRY, 2022–2029 (USD MILLION) 142
TABLE 36 ASIA PACIFIC: ASSAY KITS MARKETS, BY COUNTRY, 2022–2029 (USD MILLION) 142
TABLE 37 LATIN AMERICA: ASSAY KITS MARKETS, BY COUNTRY, 2022–2029 (USD MILLION) 142
TABLE 38 MIDDLE EAST: ASSAY KITS MARKETS, BY REGION, 2022–2029 (USD MILLION) 143
TABLE 39 GCC COUNTRIES: ASSAY KITS MARKETS, BY COUNTRY, 2022–2029 (USD MILLION) 143
6.2.2 REAGENTS & CHEMICALS 143
6.2.2.1 Recurrent usage in drug discovery & development to boost demand 143
TABLE 40 REAGENTS & CHEMICALS MARKET, BY REGION, 2022–2029 (USD MILLION) 144
TABLE 41 NORTH AMERICA: REAGENTS & CHEMICALS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 145
TABLE 42 EUROPE: REAGENTS & CHEMICALS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 145
TABLE 43 ASIA PACIFIC: REAGENTS & CHEMICALS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 146
TABLE 44 LATIN AMERICA: REAGENTS & CHEMICALS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 146
TABLE 45 MIDDLE EAST: REAGENTS & CHEMICALS MARKET, BY REGION, 2022–2029 (USD MILLION) 146
TABLE 46 GCC COUNTRIES: REAGENTS & CHEMICALS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 147
6.2.3 COLUMNS & FILTERS 147
6.2.3.1 High uptake across end-user facilities to support market growth 147
TABLE 47 COLUMNS & FILTERS MARKET, BY REGION, 2022–2029 (USD MILLION) 148
TABLE 48 NORTH AMERICA: COLUMNS & FILTERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 148
TABLE 49 EUROPE: COLUMNS & FILTERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 148
TABLE 50 ASIA PACIFIC: COLUMNS & FILTERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 149
TABLE 51 LATIN AMERICA: COLUMNS & FILTERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 149
TABLE 52 MIDDLE EAST: COLUMNS & FILTERS MARKET, BY REGION, 2022–2029 (USD MILLION) 149
TABLE 53 GCC COUNTRIES: COLUMNS & FILTERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 150
6.3 SERVICES 150
6.3.1 INCREASING NUMBER OF CROS TO DRIVE MARKET 150
TABLE 54 BIOMARKER SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 151
TABLE 55 NORTH AMERICA: BIOMARKER SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 152
TABLE 56 EUROPE: BIOMARKER SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 152
TABLE 57 ASIA PACIFIC: BIOMARKER SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 152
TABLE 58 LATIN AMERICA: BIOMARKER SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 153
TABLE 59 MIDDLE EAST: BIOMARKER SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 153
TABLE 60 GCC COUNTRIES: BIOMARKER SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 153
6.4 SOFTWARE 154
6.4.1 INCREASING ADOPTION OF BIOINFORMATICS TOOLS TO DRIVE MARKET 154
TABLE 61 SOFTWARE MARKET, BY REGION, 2022–2029 (USD MILLION) 154
TABLE 62 NORTH AMERICA: SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 155
TABLE 63 EUROPE: SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 155
TABLE 64 ASIA PACIFIC: SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 155
TABLE 65 LATIN AMERICA: SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 156
TABLE 66 MIDDLE EAST: SOFTWARE MARKET, BY REGION,2022–2029 (USD MILLION) 156
TABLE 67 GCC COUNTRIES: SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 156
7 BIOMARKERS MARKET, BY TYPE 157
7.1 INTRODUCTION 158
TABLE 68 BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 158
7.2 SAFETY BIOMARKERS 158
7.2.1 ABILITY TO MEASURE ADVERSE EFFECTS TO PROPEL MARKET 158
TABLE 69 SAFETY BIOMARKERS MARKET, BY REGION, 2022–2029 (USD MILLION) 159
TABLE 70 NORTH AMERICA: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 159
TABLE 71 EUROPE: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 160
TABLE 72 ASIA PACIFIC: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 160
TABLE 73 LATIN AMERICA: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 161
TABLE 74 MIDDLE EAST: SAFETY BIOMARKERS MARKET, BY REGION, 2022–2029 (USD MILLION) 161
TABLE 75 GCC COUNTRIES: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 161
7.3 EFFICACY BIOMARKERS 162
TABLE 76 EFFICACY BIOMARKERS MARKET, BY REGION, 2022–2029 (USD MILLION) 162
TABLE 77 NORTH AMERICA: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 162
TABLE 78 EUROPE: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 163
TABLE 79 ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 163
TABLE 80 LATIN AMERICA: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 164
TABLE 81 MIDDLE EAST: EFFICACY BIOMARKERS MARKET, BY REGION, 2022–2029 (USD MILLION) 164
TABLE 82 GCC COUNTRIES: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 164
TABLE 83 EFFICACY BIOMARKERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 165
7.3.1 PREDICTIVE BIOMARKERS 165
7.3.1.1 Ease of patient identification to support market growth 165
TABLE 84 PREDICTIVE BIOMARKERS MARKET, BY REGION, 2022–2029 (USD MILLION) 166
TABLE 85 NORTH AMERICA: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 166
TABLE 86 EUROPE: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 167
TABLE 87 ASIA PACIFIC: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 167
TABLE 88 LATIN AMERICA: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 168
TABLE 89 MIDDLE EAST: PREDICTIVE BIOMARKERS MARKET, BY REGION, 2022–2029 (USD MILLION) 168
TABLE 90 GCC COUNTRIES: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 168
7.3.2 SURROGATE BIOMARKERS 169
7.3.2.1 Ease of tracking treatment effectiveness to drive adoption 169
TABLE 91 SURROGATE BIOMARKERS MARKET, BY REGION, 2022–2029 (USD MILLION) 169
TABLE 92 NORTH AMERICA: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 170
TABLE 93 EUROPE: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 170
TABLE 94 ASIA PACIFIC: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 170
TABLE 95 LATIN AMERICA: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 171
TABLE 96 MIDDLE EAST: SURROGATE BIOMARKERS MARKET, BY REGION, 2022–2029 (USD MILLION) 171
TABLE 97 GCC COUNTRIES: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 171
7.3.3 PHARMACODYNAMIC BIOMARKERS 172
7.3.3.1 High uptake in selection and optimization of drug doses to drive market 172
TABLE 98 PHARMACODYNAMIC BIOMARKERS MARKET, BY REGION, 2022–2029 (USD MILLION) 172
TABLE 99 NORTH AMERICA: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 173
TABLE 100 EUROPE: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 173
TABLE 101 ASIA PACIFIC: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 173
TABLE 102 LATIN AMERICA: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 174
TABLE 103 MIDDLE EAST: PHARMACODYNAMIC BIOMARKERS MARKET, BY REGION, 2022–2029 (USD MILLION) 174
TABLE 104 GCC COUNTRIES: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 174
7.3.4 PROGNOSTIC BIOMARKERS 175
7.3.4.1 Ability to predict health outcomes without therapeutic intervention to propel adoption 175
TABLE 105 PROGNOSTIC BIOMARKERS MARKET, BY REGION, 2022–2029 (USD MILLION) 175
TABLE 106 NORTH AMERICA: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 176
TABLE 107 EUROPE: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 176
TABLE 108 ASIA PACIFIC: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 176
TABLE 109 LATIN AMERICA: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 177
TABLE 110 MIDDLE EAST: PROGNOSTIC BIOMARKERS MARKET, BY REGION, 2022–2029 (USD MILLION) 177
TABLE 111 GCC COUNTRIES: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 177
7.4 VALIDATION BIOMARKERS 178
7.4.1 INCREASING ADOPTION BY REGULATORY AGENCIES FOR THERAPEUTIC COMMERCIALIZATION TO DRIVE MARKET 178
TABLE 112 VALIDATION BIOMARKERS MARKET, BY REGION, 2022–2029 (USD MILLION) 178
TABLE 113 NORTH AMERICA: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 179
TABLE 114 EUROPE: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 179
TABLE 115 ASIA PACIFIC: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 179
TABLE 116 LATIN AMERICA: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 180
TABLE 117 MIDDLE EAST: VALIDATION BIOMARKERS MARKET, BY REGION, 2022–2029 (USD MILLION) 180
TABLE 118 GCC COUNTRIES: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 180
8 BIOMARKERS MARKET, BY RESEARCH AREA 181
8.1 INTRODUCTION 182
TABLE 119 BIOMARKERS MARKET, BY RESEARCH AREA, 2022–2029 (USD MILLION) 182
8.2 GENOMICS 182
8.2.1 RISING TECHNOLOGICAL ADVANCEMENTS FOR BIOMARKER TESTING TO PROPEL MARKET 182
TABLE 120 BIOMARKERS MARKET FOR GENOMICS, BY REGION, 2022–2029 (USD MILLION) 183
TABLE 121 NORTH AMERICA: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2022–2029 (USD MILLION) 183
TABLE 122 EUROPE: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2022–2029 (USD MILLION) 184
TABLE 123 ASIA PACIFIC: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2022–2029 (USD MILLION) 184
TABLE 124 LATIN AMERICA: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2022–2029 (USD MILLION) 185
TABLE 125 MIDDLE EAST: BIOMARKERS MARKET FOR GENOMICS, BY REGION, 2022–2029 (USD MILLION) 185
TABLE 126 GCC COUNTRIES: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2022–2029 (USD MILLION) 185
8.3 PROTEOMICS 186
8.3.1 RISING INCIDENCE OF CHRONIC DISEASES TO BOOST DEMAND 186
TABLE 127 BIOMARKERS MARKET FOR PROTEOMICS, BY REGION, 2022–2029 (USD MILLION) 186
TABLE 128 NORTH AMERICA: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2022–2029 (USD MILLION) 187
TABLE 129 EUROPE: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2022–2029 (USD MILLION) 187
TABLE 130 ASIA PACIFIC: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2022–2029 (USD MILLION) 188
TABLE 131 LATIN AMERICA: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2022–2029 (USD MILLION) 188
TABLE 132 MIDDLE EAST: BIOMARKERS MARKET FOR PROTEOMICS, BY REGION, 2022–2029 (USD MILLION) 188
TABLE 133 GCC COUNTRIES: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2022–2029 (USD MILLION) 189
8.4 METABOLOMICS 189
8.4.1 RISING INCIDENCE OF DIABETES AND OBESITY-RELATED CONDITIONS TO SUPPORT MARKET GROWTH 189
TABLE 134 BIOMARKERS MARKET FOR METABOLOMICS, BY REGION, 2022–2029 (USD MILLION) 190
TABLE 135 NORTH AMERICA: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2022–2029 (USD MILLION) 190
TABLE 136 EUROPE: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2022–2029 (USD MILLION) 190
TABLE 137 ASIA PACIFIC: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2022–2029 (USD MILLION) 191
TABLE 138 LATIN AMERICA: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2022–2029 (USD MILLION) 191
TABLE 139 MIDDLE EAST: BIOMARKERS MARKET FOR METABOLOMICS, BY REGION, 2022–2029 (USD MILLION) 191
TABLE 140 GCC COUNTRIES: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2022–2029 (USD MILLION) 192
8.5 OTHER RESEARCH AREAS 192
TABLE 141 BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY REGION, 2022–2029 (USD MILLION) 192
TABLE 142 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2022–2029 (USD MILLION) 193
TABLE 143 EUROPE: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2022–2029 (USD MILLION) 193
TABLE 144 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2022–2029 (USD MILLION) 194
TABLE 145 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2022–2029 (USD MILLION) 194
TABLE 146 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY REGION, 2022–2029 (USD MILLION) 194
TABLE 147 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2022–2029 (USD MILLION) 195
 
9 BIOMARKERS MARKET, BY TECHNOLOGY 196
9.1 INTRODUCTION 197
TABLE 148 BIOMARKERS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 197
9.2 IMMUNOASSAYS 197
TABLE 149 IMMUNOASSAYS MARKET, BY TYPE, 2022–2029 (USD MILLION) 198
TABLE 150 IMMUNOASSAYS MARKET, BY REGION, 2022–2029 (USD MILLION) 198
TABLE 151 NORTH AMERICA: IMMUNOASSAYS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 198
TABLE 152 EUROPE: IMMUNOASSAYS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 199
TABLE 153 ASIA PACIFIC: IMMUNOASSAYS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 199
TABLE 154 LATIN AMERICA: IMMUNOASSAYS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 200
TABLE 155 MIDDLE EAST: IMMUNOASSAYS MARKET, BY REGION, 2022–2029 (USD MILLION) 200
TABLE 156 GCC COUNTRIES: IMMUNOASSAYS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 200
9.2.1 ELISA 201
9.2.1.1 ELISA to hold largest market share 201
TABLE 157 ELISA MARKET, BY REGION, 2022–2029 (USD MILLION) 202
TABLE 158 NORTH AMERICA: ELISA MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 202
TABLE 159 EUROPE: ELISA MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 202
TABLE 160 ASIA PACIFIC: ELISA MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 203
TABLE 161 LATIN AMERICA: ELISA MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 203
TABLE 162 MIDDLE EAST: ELISA MARKET, BY REGION, 2022–2029 (USD MILLION) 203
TABLE 163 GCC COUNTRIES: ELISA MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 204
9.2.2 PROTEIN MICROARRAYS 204
9.2.2.1 Cost efficIency and high sensitivity to propel adoption 204
TABLE 164 PROTEIN MICROARRAYS MARKET, BY REGION, 2022–2029 (USD MILLION) 205
TABLE 165 NORTH AMERICA: PROTEIN MICROARRAYS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 205
TABLE 166 EUROPE: PROTEIN MICROARRAYS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 206
TABLE 167 ASIA PACIFIC: PROTEIN MICROARRAYS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 206
TABLE 168 LATIN AMERICA: PROTEIN MICROARRAYS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 207
TABLE 169 MIDDLE EAST: PROTEIN MICROARRAYS MARKET, BY REGION, 2022–2029 (USD MILLION) 207
TABLE 170 GCC COUNTRIES: PROTEIN MICROARRAYS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 207
9.2.3 WESTERN BLOT 208
9.2.3.1 Increasing utilization in translation medicine to drive market 208
TABLE 171 WESTERN BLOT MARKET, BY REGION, 2022–2029 (USD MILLION) 208
TABLE 172 NORTH AMERICA: WESTERN BLOT MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 208
TABLE 173 EUROPE: WESTERN BLOT MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 208
TABLE 174 ASIA PACIFIC: WESTERN BLOT MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 209
TABLE 175 LATIN AMERICA: WESTERN BLOT MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 210
TABLE 176 MIDDLE EAST: WESTERN BLOT MARKET, BY REGION, 2022–2029 (USD MILLION) 210
TABLE 177 GCC COUNTRIES: WESTERN BLOT MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 210
9.3 NGS 211
9.3.1 TECHNOLOGICAL ADVANCEMENTS IN NGS PLATFORMS TO BOOST DEMAND 211
TABLE 178 NGS MARKET, BY REGION, 2022–2029 (USD MILLION) 212
TABLE 179 NORTH AMERICA: NGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 212
TABLE 180 EUROPE: NGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 212
TABLE 181 ASIA PACIFIC: NGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 213
TABLE 182 LATIN AMERICA: NGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 213
TABLE 183 MIDDLE EAST: NGS MARKET, BY REGION, 2022–2029 (USD MILLION) 213
TABLE 184 GCC COUNTRIES: NGS MARKET, 2022–2029 (USD MILLION) 214
9.4 PCR 214
9.4.1 RAPID AND SENSITIVE DETECTION OF GENETIC BIOMARKERS TO DRIVE MARKET 214
TABLE 185 PCR MARKET, BY REGION, 2022–2029 (USD MILLION) 215
TABLE 186 NORTH AMERICA: PCR MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 215
TABLE 187 EUROPE: PCR MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 215
TABLE 188 ASIA PACIFIC: PCR MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 216
TABLE 189 LATIN AMERICA: PCR MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 216
TABLE 190 MIDDLE EAST: PCR MARKET, BY REGION, 2022–2029 (USD MILLION) 216
TABLE 191 GCC COUNTRIES: PCR MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 217
9.5 MASS SPECTROMETRY 217
9.5.1 INTEGRATION WITH OMICS TECHNOLOGIES TO DRIVE MARKET 217
TABLE 192 MASS SPECTROMETRY MARKET, BY REGION, 2022–2029 (USD MILLION) 218
TABLE 193 NORTH AMERICA: MASS SPECTROMETRY MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 218
TABLE 194 EUROPE: MASS SPECTROMETRY MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 218
TABLE 195 ASIA PACIFIC: MASS SPECTROMETRY MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 219
TABLE 196 LATIN AMERICA: MASS SPECTROMETRY MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 219
TABLE 197 MIDDLE EAST: MASS SPECTROMETRY MARKET, BY REGION, 2022–2029 (USD MILLION) 219
TABLE 198 GCC COUNTRIES: MASS SPECTROMETRY MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 220
 
9.6 CHROMATOGRAPHY 220
9.6.1 UTILIZATION IN PROTEOMICS RESEARCH TO SUPPORT MARKET GROWTH 220
TABLE 199 CHROMATOGRAPHY MARKET, BY REGION, 2022–2029 (USD MILLION) 221
TABLE 200 NORTH AMERICA: CHROMATOGRAPHY MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 221
TABLE 201 EUROPE: CHROMATOGRAPHY MARKET, BY COUNTRY,2022–2029 (USD MILLION) 221
TABLE 202 ASIA PACIFIC: CHROMATOGRAPHY MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 222
TABLE 203 LATIN AMERICA: CHROMATOGRAPHY MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 222
TABLE 204 MIDDLE EAST: CHROMATOGRAPHY MARKET, BY REGION, 2022–2029 (USD MILLION) 222
TABLE 205 GCC COUNTRIES: CHROMATOGRAPHY MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 223
9.7 OTHER TECHNOLOGIES 223
TABLE 206 OTHER TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION) 224
TABLE 207 NORTH AMERICA: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 224
TABLE 208 EUROPE: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 224
TABLE 209 ASIA PACIFIC: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 225
TABLE 210 LATIN AMERICA: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 225
TABLE 211 MIDDLE EAST: OTHER TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION) 225
TABLE 212 GCC COUNTRIES: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 226
10 BIOMARKERS MARKET, BY DISEASE INDICATION 227
10.1 INTRODUCTION 228
TABLE 213 BIOMARKERS MARKET, BY DISEASE INDICATION, 2022–2029 (USD MILLION) 228
10.2 CANCER 228
10.2.1 RISING INCIDENCE OF CANCER AND GROWING FOCUS ON EARLY DISEASE DETECTION TO PROPEL MARKET 228
TABLE 214 LIST OF FDA-APPROVED BIOMARKERS FOR CANCER, BY TYPE 229
TABLE 215 BIOMARKERS MARKET FOR CANCER, BY REGION, 2022–2029 (USD MILLION) 230
TABLE 216 NORTH AMERICA: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 230
TABLE 217 EUROPE: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 230
TABLE 218 ASIA PACIFIC: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 231
TABLE 219 LATIN AMERICA: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 231
TABLE 220 MIDDLE EAST: BIOMARKERS MARKET FOR CANCER, BY REGION, 2022–2029 (USD MILLION) 231
TABLE 221 GCC COUNTRIES: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 232
10.3 INFECTIOUS DISEASES 232
10.3.1 INCREASING INCIDENCE OF HIV AND TB TO BOOST DEMAND 232
TABLE 222 BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022–2029 (USD MILLION) 233
TABLE 223 NORTH AMERICA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 233
TABLE 224 EUROPE: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 234
TABLE 225 ASIA PACIFIC: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 234
TABLE 226 LATIN AMERICA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 235
TABLE 227 MIDDLE EAST: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022–2029 (USD MILLION) 235
TABLE 228 GCC COUNTRIES: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 235
10.4 IMMUNOLOGICAL DISORDERS 236
10.4.1 RISING ADOPTION OF ASSAYS FOR AUTOIMMUNE DISEASE DETECTION TO DRIVE MARKET 236
TABLE 229 BIOMARKERS FOR IMMUNOLOGICAL DISORDERS 236
TABLE 230 BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2022–2029 (USD MILLION) 237
TABLE 231 NORTH AMERICA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 237
TABLE 232 EUROPE: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 238
TABLE 233 ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 238
TABLE 234 LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 239
TABLE 235 MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2022–2029 (USD MILLION) 239
TABLE 236 GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 239
10.5 NEUROLOGICAL DISORDERS 240
10.5.1 HIGH UPTAKE OF ELISA FOR DIAGNOSIS TO SUPPORT MARKET GROWTH 240
TABLE 237 BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2022–2029 (USD MILLION) 240
TABLE 238 NORTH AMERICA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 241
TABLE 239 EUROPE: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 241
TABLE 240 ASIA PACIFIC: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 242
TABLE 241 LATIN AMERICA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 242
TABLE 242 MIDDLE EAST: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2022–2029 (USD MILLION) 242
TABLE 243 GCC COUNTRIES: BIOMARKERS MARKET FOR CANCER, BY NEUROLOGICAL DISORDERS, 2022–2029 (USD MILLION) 243
10.6 CARDIOVASCULAR DISORDERS 243
10.6.1 TECHNOLOGICAL ADVANCEMENTS IN CARDIAC BIOMARKERS TO BOOST DEMAND 243
TABLE 244 BIOMARKERS FOR CARDIOVASCULAR DISORDERS 244
TABLE 245 BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION, 2022–2029 (USD MILLION) 244
TABLE 246 NORTH AMERICA: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 245
TABLE 247 EUROPE: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 245
TABLE 248 ASIA PACIFIC: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 246
TABLE 249 LATIN AMERICA: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 246
TABLE 250 MIDDLE EAST: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION, 2022–2029 (USD MILLION) 246
TABLE 251 GCC COUNTRIES: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 247
10.7 OTHER DISEASE INDICATIONS 247
TABLE 252 BIOMARKERS FOR RENAL DISORDERS 248
TABLE 253 BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2022–2029 (USD MILLION) 248
TABLE 254 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 249
TABLE 255 EUROPE: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 249
TABLE 256 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 250
TABLE 257 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 250
TABLE 258 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2022–2029 (USD MILLION) 250
TABLE 259 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 251